Pharmaceutical salts of a chk-1 inhibitor
AssigneesSentinel Oncology Limited, Pharmaengine, Inc.
InventorsMeriel MAJOR, Stuart TRAVERS, Jake PARKER, Julian NORTHEN
Life of this patent
Estimating the term…
Abstract
The invention provides a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile which is selected from maleate, tosylate, besylate and malonate salts. Also provided are particular crystalline forms of the salts, methods for the preparation of the salts, pharmaceutical compositions containing the salts and their therapeutic uses.
Claims21
A pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile which is selected from maleate, tosylate, besylate and malonate salts.
(canceled)
Dependencies are inferred from the claim text.